Cox regression model of OS and PFS survival based on ALCL genetics
| Analysis . | Gene rearranged . | N* . | No. of events . | Unadjusted . | Adjusted for age and IPI . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | Genetic P value . | HR . | 95% CI . | P value . | Genetic P value . | ||||
| All patients, OS | ALK | 29 | 6 | Reference | 1.09E-05 | Reference | 7.10E-05 | ||||
| DUSP22 | 21 | 4 | 0.95 | 0.27-3.36 | .9500 | 0.58 | 0.12-2.79 | .5000 | |||
| TP63 | 6 | 6 | 11.01 | 3.42-35.50 | <.0001 | 8.63 | 2.08-35.77 | .0030 | |||
| −/−/− | 40 | 26 | 5.20 | 2.10-12.86 | .0004 | 4.16 | 1.32-13.09 | .0150 | |||
| All patients, PFS | ALK | 27 | 11 | Reference | 0.0020 | Reference | .01390 | ||||
| DUSP22 | 10 | 7 | 1.38 | 0.51-3.74 | .5300 | 0.76 | 0.23-2.44 | .6400 | |||
| TP63 | 6 | 6 | 5.02 | 1.82-13.82 | .0018 | 3.48 | 1.13-10.69 | .0300 | |||
| −/−/− | 30 | 27 | 3.01 | 1.48-6.14 | .0025 | 2.32 | 1.05-5.13 | .0380 | |||
| Anthracycline-treated, OS | ALK | 21 | 4 | Reference | 1.02E-05 | Reference | .00026 | ||||
| DUSP22 | 18 | 2 | 0.52 | 0.10-2.86 | .4500 | 0.41 | 0.07-2.55 | .3400 | |||
| TP63 | 5 | 5 | 11.17 | 2.79-44.77 | .0007 | 9.53 | 2.04-44.49 | .0041 | |||
| −/−/− | 27 | 17 | 5.51 | 1.74-17.43 | .0037 | 4.19 | 1.20-14.64 | .0250 | |||
| Nontransplanted, OS | ALK | 21 | 4 | Reference | 4.96E-05 | Reference | .00065 | ||||
| DUSP22 | 15 | 3 | 0.95 | 0.21-4.27 | .9500 | 0.51 | 0.08-3.14 | .4700 | |||
| TP63 | 5 | 5 | 9.90 | 2.61-37.58 | .0008 | 7.72 | 1.72-34.53 | .0075 | |||
| −/−/− | 34 | 23 | 5.02 | 1.73-14.58 | .0030 | 3.27 | 1.00-10.70 | .0500 | |||
| Analysis . | Gene rearranged . | N* . | No. of events . | Unadjusted . | Adjusted for age and IPI . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | Genetic P value . | HR . | 95% CI . | P value . | Genetic P value . | ||||
| All patients, OS | ALK | 29 | 6 | Reference | 1.09E-05 | Reference | 7.10E-05 | ||||
| DUSP22 | 21 | 4 | 0.95 | 0.27-3.36 | .9500 | 0.58 | 0.12-2.79 | .5000 | |||
| TP63 | 6 | 6 | 11.01 | 3.42-35.50 | <.0001 | 8.63 | 2.08-35.77 | .0030 | |||
| −/−/− | 40 | 26 | 5.20 | 2.10-12.86 | .0004 | 4.16 | 1.32-13.09 | .0150 | |||
| All patients, PFS | ALK | 27 | 11 | Reference | 0.0020 | Reference | .01390 | ||||
| DUSP22 | 10 | 7 | 1.38 | 0.51-3.74 | .5300 | 0.76 | 0.23-2.44 | .6400 | |||
| TP63 | 6 | 6 | 5.02 | 1.82-13.82 | .0018 | 3.48 | 1.13-10.69 | .0300 | |||
| −/−/− | 30 | 27 | 3.01 | 1.48-6.14 | .0025 | 2.32 | 1.05-5.13 | .0380 | |||
| Anthracycline-treated, OS | ALK | 21 | 4 | Reference | 1.02E-05 | Reference | .00026 | ||||
| DUSP22 | 18 | 2 | 0.52 | 0.10-2.86 | .4500 | 0.41 | 0.07-2.55 | .3400 | |||
| TP63 | 5 | 5 | 11.17 | 2.79-44.77 | .0007 | 9.53 | 2.04-44.49 | .0041 | |||
| −/−/− | 27 | 17 | 5.51 | 1.74-17.43 | .0037 | 4.19 | 1.20-14.64 | .0250 | |||
| Nontransplanted, OS | ALK | 21 | 4 | Reference | 4.96E-05 | Reference | .00065 | ||||
| DUSP22 | 15 | 3 | 0.95 | 0.21-4.27 | .9500 | 0.51 | 0.08-3.14 | .4700 | |||
| TP63 | 5 | 5 | 9.90 | 2.61-37.58 | .0008 | 7.72 | 1.72-34.53 | .0075 | |||
| −/−/− | 34 | 23 | 5.02 | 1.73-14.58 | .0030 | 3.27 | 1.00-10.70 | .0500 | |||
−/−/−, triple-negative ALCL.
The numbers of patients with OS and PFS data are different from the total number of patients in Table 1 because some patients did not have follow-up data available (missing OS data: 3 ALK, 1 DUSP22, 5 −/−/−; missing PFS data: 5 ALK, 12 DUSP22, 15 −/−/−).